Barclays
UBX

Barclays’s Unity Biotechnology UBX Stock Holding History

Barclays’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-600
Closed -$18K – 4748
2021
Q3 		$18K Sell
600
-386
-39% -$13.6K ﹤0.01% 4423
2021
Q2 		$45K Sell
986
-1,998
-67% -$96.2K ﹤0.01% 4180
2021
Q1 		$178K Buy
2,984
+1,817
+156% +$124K ﹤0.01% 3764
2020
Q4 		$61K Sell
1,167
-447
-28% -$21.6K ﹤0.01% 4332
2020
Q3 		$55K Sell
1,614
-239
-13% -$15.1K ﹤0.01% 4553
2020
Q2 		$160K Buy
1,853
+902
+95% +$66.9K ﹤0.01% 4228
2020
Q1 		$56K Sell
951
-1,984
-68% -$125K ﹤0.01% 5162
2019
Q4 		$212K Buy
2,935
+1,538
+110% +$109K ﹤0.01% 4996
2019
Q3 		$85K Sell
1,397
-1,205
-46% -$85.2K ﹤0.01% 5599
2019
Q2 		$247K Buy
2,602
+459
+21% +$39.1K ﹤0.01% 4920
2019
Q1 		$174K Buy
2,143
+2,003
+1,431% +$227K ﹤0.01% 4929
2018
Q4 		$23K Sell
140
-73
-34% -$9.69K ﹤0.01% 5840
2018
Q3 		$35K Buy
213
+56
+36% +$9.22K ﹤0.01% 6257
2018
Q2 		$24K Buy
+157
New +$22.9K ﹤0.01% 6079

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Barclays's UBX Position: Q4 2021 in Review

Barclays sold out of Unity Biotechnology (UBX) in Q4 2021, closing a stake of 600 shares — an estimated $18K sold.

Barclays first reported a position in UBX in Q2 2018 and held it in 14 quarters. The position peaked at $247K in Q2 2019. 71 funds tracked by Wall St. Rank hold UBX as of Q4 2021.

  • Barclays reported no remaining Unity Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Barclays sold 600 Unity Biotechnology shares in Q4 2021, an estimated $18K.
  • Barclays first reported a position in Unity Biotechnology in Q2 2018 and held it in 14 quarters.
  • Barclays's Unity Biotechnology position peaked at $247K in Q2 2019.
  • 71 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.